Novo says the shot cut weight 25% at 68 weeks across 1,900 women versus about 3% on placebo. Zacks pitches three weight loss ETFs on the back of it.
Recap by typeshit. Full story at Yahoo Finance.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
An endocrinologist gives a general explainer on who these weight loss injections may suit and how they work, aimed at people with obesity or constant hunger.
Kieran Didi says the model beat everything the team compared it against on speed and quality, both in computer tests and in the lab.
Loading…